Why did IDIA.SW stock jump today?

IDIA.SW stock rose on higher volume and renewed focus on its pipeline and QUVIVIQ commercial updates. Traders also positioned ahead of the 2026-02-26 earnings date, increasing intraday demand.

What is Meyka AI's price forecast for IDIA.SW stock?

Meyka AI's forecast model projects **CHF 5.91** in one year for IDIA.SW stock, implying about **55.99%** upside versus the current **CHF 3.79**. Forecasts are model-based and not guarantees.

How does IDIA.SW stock compare to the Healthcare sector?

IDIA.SW stock shows negative earnings and a trailing PE of **-6.06**, unlike the Healthcare sector average PE of **34.40**. The difference reflects Idorsia’s development-stage profile and high R&D spend.

What are the main risks for IDIA.SW stock?

Main risks include clinical trial failures, slower-than-expected product uptake, and cash burn from R&D. Negative EPS and weak cash metrics increase sensitivity to operational setbacks.

CH Stocks

IDIA.SW stock up 8.13% to CHF 3.79 on SIX intraday: volume surge signals momentum

ByDanny Kontos January 23, 2026January 23, 2026

IDIA.SW stock jumped 8.13% to CHF 3.79 on the SIX market intraday, led by heavier trading and a price close above the 50-day average. Volume reached 290,542 shares versus a 50-day average near 1,490,561, showing a clear short-term surge. Investors noted pipeline updates for QUVIVIQ and upcoming catalysts ahead of the 2026 earnings announcement. We examine why Idorsia Ltd (IDIA.SW) is a top gainer today and what that means for holders and traders.